295 related articles for article (PubMed ID: 21777638)
1. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.
Osorio JE; Huang CY; Kinney RM; Stinchcomb DT
Vaccine; 2011 Sep; 29(42):7251-60. PubMed ID: 21777638
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice.
Brewoo JN; Kinney RM; Powell TD; Arguello JJ; Silengo SJ; Partidos CD; Huang CY; Stinchcomb DT; Osorio JE
Vaccine; 2012 Feb; 30(8):1513-20. PubMed ID: 22178727
[TBL] [Abstract][Full Text] [Related]
3. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
Osorio JE; Wallace D; Stinchcomb DT
Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.
Osorio JE; Velez ID; Thomson C; Lopez L; Jimenez A; Haller AA; Silengo S; Scott J; Boroughs KL; Stovall JL; Luy BE; Arguello J; Beatty ME; Santangelo J; Gordon GS; Huang CY; Stinchcomb DT
Lancet Infect Dis; 2014 Sep; 14(9):830-8. PubMed ID: 25087476
[TBL] [Abstract][Full Text] [Related]
5. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).
Huang CY; Kinney RM; Livengood JA; Bolling B; Arguello JJ; Luy BE; Silengo SJ; Boroughs KL; Stovall JL; Kalanidhi AP; Brault AC; Osorio JE; Stinchcomb DT
PLoS Negl Trop Dis; 2013; 7(5):e2243. PubMed ID: 23738026
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.
Osorio JE; Brewoo JN; Silengo SJ; Arguello J; Moldovan IR; Tary-Lehmann M; Powell TD; Livengood JA; Kinney RM; Huang CY; Stinchcomb DT
Am J Trop Med Hyg; 2011 Jun; 84(6):978-87. PubMed ID: 21633037
[TBL] [Abstract][Full Text] [Related]
7. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
[TBL] [Abstract][Full Text] [Related]
8. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
9. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
Guy B; Jackson N
Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
[TBL] [Abstract][Full Text] [Related]
11. Vaccines licensed and in clinical trials for the prevention of dengue.
Torresi J; Ebert G; Pellegrini M
Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864
[TBL] [Abstract][Full Text] [Related]
12. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.
Huang CY; Butrapet S; Tsuchiya KR; Bhamarapravati N; Gubler DJ; Kinney RM
J Virol; 2003 Nov; 77(21):11436-47. PubMed ID: 14557629
[TBL] [Abstract][Full Text] [Related]
13. Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.
Durbin AP
Curr Opin Virol; 2020 Aug; 43():79-87. PubMed ID: 33164790
[TBL] [Abstract][Full Text] [Related]
14. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.
Huang CY; Butrapet S; Pierro DJ; Chang GJ; Hunt AR; Bhamarapravati N; Gubler DJ; Kinney RM
J Virol; 2000 Apr; 74(7):3020-8. PubMed ID: 10708416
[TBL] [Abstract][Full Text] [Related]
15. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.
Huang CY; Silengo SJ; Whiteman MC; Kinney RM
J Virol; 2005 Jun; 79(12):7300-10. PubMed ID: 15919884
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E
J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical development of a dengue recombinant subunit vaccine.
Manoff SB; George SL; Bett AJ; Yelmene ML; Dhanasekaran G; Eggemeyer L; Sausser ML; Dubey SA; Casimiro DR; Clements DE; Martyak T; Pai V; Parks DE; Coller BA
Vaccine; 2015 Dec; 33(50):7126-34. PubMed ID: 26458804
[TBL] [Abstract][Full Text] [Related]
18. Using recombinant DNA technology for the development of live-attenuated dengue vaccines.
Lee HC; Butler M; Wu SC
Enzyme Microb Technol; 2012 Jul; 51(2):67-72. PubMed ID: 22664189
[TBL] [Abstract][Full Text] [Related]
19. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.
Coller BA; Clements DE; Bett AJ; Sagar SL; Ter Meulen JH
Vaccine; 2011 Sep; 29(42):7267-75. PubMed ID: 21777637
[TBL] [Abstract][Full Text] [Related]
20. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
